OCHSNER HEALTH SYSTEM
🇺🇸United States
A Phase II Study of an Anti-Tumor Immunotherapy Regimen Comprised of Pegylated Interferon-Alpha 2b and HyperAcute Melanoma Vaccine for Subjects With Advanced Melanoma
Phase 2
- Conditions
- First Posted Date
- 2008-09-04
- Last Posted Date
- 2011-01-13
- Lead Sponsor
- Ochsner Health System
- Target Recruit Count
- 30
- Registration Number
- NCT00746746
- Locations
- 🇺🇸
Ochsner Health System, New Orleans, Louisiana, United States
Safety Study of UT-15C SR (Oral Treprostinil) in Patients Undergoing a Lower Limb Endovascular Procedure
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-04-03
- Last Posted Date
- 2023-04-24
- Lead Sponsor
- Ochsner Health System
- Target Recruit Count
- 7
- Registration Number
- NCT00651885
- Locations
- 🇺🇸
Ochsner Clinic Foundation, New Orleans, Louisiana, United States
© Copyright 2024. All Rights Reserved by MedPath